Unser Zentrum hat eine neue Überblicksseite. Diese Seite befindet sich im Aufbau.
UKM Prostatazentrum
NEUE WEBSITE
NEUE WEBSITE
Optimierung klinisch verfügbarer Tumormarker
- Semjonow A, Oberpenning F, Weining C, Schön M, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP: Do modifications of non-equimolar assays for total prostate specific antigen improve detection of prostate cancer? Clin Chem 47: 1472-5, 2001.
- Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP, Semjonow A: Combining free and total prostate specific antigen assays from different manufacturers: The pitfalls. Eur Urol 42: 577-82, 2002.
- Oberpenning F, Hetzel S, Weining C, Brandt B, De Angelis G, Heinecke A, Lein M, Fornara P, Schmid HP, Hertle L, Semjonow A: Semi-quantitative immunochromato-graphic test for prostate specific antigen in whole blood: Tossing the coin to predict prostate cancer? Eur Urol 43: 478-84, 2003.
- Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP, Semjonow A: A new modification of the ACS assay for total prostate specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer. Clin Chem Lab Med 41: 90–4, 2003.
- Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening SA, Jung K: A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol. 2003 Oct;170(4 Pt 1):1175-9, 2003.
- Jung K, Lein M, Stephan C, Von Hösslin K, Semjonow A, Sinha P, Loening SA, Schnorr D: Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
- Int J Cancer. 2004 Sep 20;111(5):783-91, 2004.
- Jung K, Stephan C, Semjonow A, Lein M, Schnorr D, Loening SA: Serum osteo-protegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
- J Urol. 2003 Dec;170(6 Pt 1):2302-5, 2003.
- Keller T, Butz H, Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Jung K: Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. Clin Chem. 2005 Mar; 51(3):532-9, 2005.
- Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, Haese A, Chun F, Schnorr D, Loening SA, Jung: A multicenter clinical trial on the use of (-5,-7) pro prostate specific antigen. J Urol. 2005 Dec; 174 (6): 2150-3, 2005.
- De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A: Twenty Years of PSA: From Prostate Antigen to Tumor Marker. Rev Urol. 2007 Summer; 9 (3): 113-23, 2007.
- Payne S, Serth J, Schostak M, Kamradt J, Strauss A, Thelen P, Model F, Kevin Day J, Liebenberg V, Morotti A, Yamamura S, Lograsso J, Sledziewski A, Semjonow A: DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate. 2009 May 20
- Stephan C, Bangma C, Vignati G, Bartsch G, Lein M, Jung K, Philippe M, Semjonow A, Catalona WJ: 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers. Int J Biol Markers.2009 April-June;24(2):65-69.
